The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).
 
Rushabh Kiran Kothari
Honoraria - Alkem Laboratories; AstraZeneca; Bard Peripheral Vascular; Bristol Myers Squibb Foundation (Inst); Celon Pharma (Inst); Cipla (Inst); Emcure; Fresenius Kabi; Glenmark; Merck (Inst); Novartis; Pfizer; Roche; Zydus Pharmaceuticals
Consulting or Advisory Role - MSD
Research Funding - Axis Clinicals (Inst); Lambda Therapeutic Research (Inst); Reliance Life Sciences (Inst); Zydus Pharmaceuticals (Inst)
 
Madala Ravikrishna
No Relationships to Disclose
 
Ravikant Singh
No Relationships to Disclose
 
Vikas Talreja
No Relationships to Disclose
 
Anand Bhaskarrao Pathak
No Relationships to Disclose
 
Sameer Shrirangwar
No Relationships to Disclose
 
Tanmoy Kumar Mandal
No Relationships to Disclose
 
Sudeep Das
No Relationships to Disclose
 
Siddharth Turkar
No Relationships to Disclose
 
Nikhil Pande
No Relationships to Disclose
 
Arun Chandrasekharan
No Relationships to Disclose
 
Gunjesh Kumar Singh
No Relationships to Disclose
 
Tara Chand Gupta
No Relationships to Disclose
 
Ashay Karpe
No Relationships to Disclose
 
Bhavesh Pradip Poladia
No Relationships to Disclose
 
Manuprasad Avaronnan
No Relationships to Disclose
 
Lovin Wilson
No Relationships to Disclose
 
Nirmal Vivek Raut
No Relationships to Disclose
 
Vijay Maruti Patil
Research Funding - AstraZeneca (Inst); Eisai Germany (Inst); Intas (Inst); Johnson & Johnson/Janssen (Inst); NATCO Pharma (Inst); Novartis (Inst)
 
Kumar Prabhash
No Relationships to Disclose